Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.

Respiratory medicine - 1 May 2016

Condreay Lynn, Huang Lingkang, Harris Elizabeth, Brooks Jean, Riley John H, Church Alison, Ghosh Soumitra

Abstract excerpt

BACKGROUND: Treatment with long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) for chronic obstructive pulmonary disease (COPD) is standard, but response varies. We investigated genetic association with treatment response to umeclidinium (UMEC, a LAMA), vilanterol (VI, a LABA), and combination therapy. METHODS: Data from 17 clinical trials (N = 6075) in patients with COPD receiving...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Inhalation
Share to Adrenergic beta-2 Receptor Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bronchodilator Agents

Share to Drug Combinations

Share to Forced Expiratory Volume

Share to Muscarinic Antagonists

Share to Pulmonary Disease, Chronic Obstructive

Share to Vital Capacity

Source

Identifiers

PMID: 27109822
DOI: 10.1016/j.rmed.2016.03.019

Genes

ADRB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.PMID 27109822Read ↗

Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation.Semantic proximity Read ↗

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.Semantic proximity Read ↗

The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update.Semantic proximity Read ↗

Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Semantic proximity Read ↗

Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1.Semantic proximity Read ↗

Do genetic polymorphisms alter patient response to inhaled bronchodilators?Semantic proximity Read ↗

A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease.Semantic proximity Read ↗

Pharmacogenetics of chronic obstructive pulmonary disease.Semantic proximity Read ↗

Organic cation transporter variation and response to smoking cessation therapies.Semantic proximity Read ↗

Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.Semantic proximity Read ↗

Pharmacogenetics of asthma.Semantic proximity Read ↗

A genome-wide association study of bronchodilator response in Latinos implicates rare variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.